| 27.5 0.22 (0.81%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 32.11 |
1-year : | 37.51 |
| Resists | First : | 27.5 |
Second : | 32.11 |
| Pivot price | 27.15 |
|||
| Supports | First : | 27.18 |
Second : | 26.98 |
| MAs | MA(5) : | 27.25 |
MA(20) : | 27.14 |
| MA(100) : | 24.61 |
MA(250) : | 17.84 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 67.9 |
| RSI | RSI(14): 72.8 |
|||
| 52-week | High : | 27.5 | Low : | 6.07 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SILK ] has closed Bollinger Bands are 81.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.52 - 27.6 | 27.6 - 27.69 |
| Low: | 27.23 - 27.33 | 27.33 - 27.44 |
| Close: | 27.32 - 27.47 | 27.47 - 27.64 |
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Sat, 14 Sep 2024
Acadian Asset Management LLC Sells 58,447 Shares of Silk Road Medical, Inc (NASDAQ:SILK) - MarketBeat
Fri, 13 Sep 2024
Silk Road Medical set to complete merger with Boston Scientific - Investing.com
Fri, 13 Sep 2024
Boston Scientific expected to close Silk Road Medical acquisition soon after antitrust waiting period expires - Mass Device
Thu, 12 Sep 2024
Silk Road Medical (SILK) Surged After the Acquisition News - Insider Monkey
Mon, 15 Jul 2024
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. - SILK - PR Newswire
Wed, 19 Jun 2024
Boston Scientific Acquires Silk Road Medical for $1.16B - M&A - HIT Consultant
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 97.4 (%) |
| Shares Short | 3,150 (K) |
| Shares Short P.Month | 2,570 (K) |
| EPS | -1.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.8 |
| Profit Margin | -29.6 % |
| Operating Margin | -33.6 % |
| Return on Assets (ttm) | -14.2 % |
| Return on Equity (ttm) | -36.5 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.71 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -18.97 |
| PEG Ratio | -11.7 |
| Price to Book value | 7.21 |
| Price to Sales | 5.83 |
| Price to Cash Flow | -32.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|